The use of cisplatin in the clinic began more than 45 years ago in the absence of understanding of the cellular and molecular mechanisms that underlie its efficacy 1 . Nonetheless, cisplatin has become a component of treatment regimens for at least 18 distinct tumor types 2 . However, cisplatin-induced side effects and the emergence of resistance to treatment led to the development of two derivatives, carboplatin and oxaliplatin, which have also seen considerable clinical use for a wide array of cancers. Interestingly, oxaliplatin has a side-effect profile that differs from those of cisplatin and carboplatin, and it is used in colorectal and other gastrointestinal cancers, against which cisplatin and carboplatin have minimal efficacy. The decision to use oxaliplatin to treat colorectal cancer was motivated primarily by its activity against colorectal cancer cell lines, rather than because of any rationale involving its mechanism of action 3, 4 . Although the assumption has been that oxaliplatin, as does cisplatin, kills cells by eliciting a DNAdamage response, no satisfactory explanation for the unique clinical use and side-effect profile of oxaliplatin has been identified. Here we demonstrate that oxaliplatin acts through a fundamentally distinct mechanism of action relative to that of cisplatin, and we propose that these agents should be used in a mechanism-targeted manner for the treatment of cancer.
RESULTS

Diverse mechanisms of action for platinum compounds
To examine the mechanism of action of cisplatin and its platinum analogs, we used an RNAi-based functional genetic strategy to predict the mechanism of cytotoxic drug action [5] [6] [7] . This methodology has the advantages of being mammalian, isogenic and unbiased by dosage effects resulting from export or metabolism. Additionally, it has previously been used to characterize the mechanism of action of other metal-based anti-cancer agents [8] [9] [10] [11] [12] [13] [14] [15] . It is based on a fluorescence competition assay that uses lymphoma cells partially infected with eight short hairpin RNAs (shRNAs) that target distinct genes encoding proteins with known or putative roles in cell-death signaling pathways: p53 (Trp53), Chk2 (Chek2), Chk1 (Chek1), ATR (Atr), ATX (Smg1), DNAPKcs (Prkdc), Bok (Bok) and Bim (Bcl2l11). The shRNA-bearing cells either enrich or deplete relative to the uninfected population, depending on the survival advantage or disadvantage conferred by a given shRNA (Fig. 1a) . The combined responses of these cells to different drugs constitute drug 'signatures. ' Signatures of all classes of clinically used cytotoxic agents have been generated and assembled into a reference set separated into eight distinct drug categories, which are based on the constituents' shared molecular mechanism of action (Supplementary Table 1) . A new drug signature can then be classified by a probabilistic K-nearest neighbors algorithm to determine whether a drug belongs to a class in the reference set or requires a new category not represented therein (Fig. 1b) .
To eliminate dosage or potency effects from confounding the RNAi signatures, all agents were administered at a concentration that killed 80-90% (lethal dose (LD) [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] ) of the cells at 48 h. LD 80-90 concentrations varied greatly from one compound to the next (Supplementary Fig. 1a) . However, through atomic-absorption spectroscopy, we determined that, for cisplatin analogs representing low, medium and high potency, the a r t i c l e s amount of platinum required inside the cells for killing corresponded to their respective LD [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] values (Supplementary Fig. 1b ). For instance, pyriplatin treatment at LD 80-90 led to much more intracellular platinum than the other LD 80-90 treatments, indicating that each molecule of pyriplatin is relatively less toxic. Thus, differences in cellular uptake were controlled effectively by using LD 80-90 concentrations.
Next, to examine the mechanisms of action of cisplatin, carboplatin, and oxaliplatin, we obtained their RNAi signatures. Cisplatin and carboplatin were both predicted to be DNA cross-linkers (Fig. 1c,d , Supplementary Table 2 , and Supplementary Fig. 2a) . Previously, the three US Food and Drug Administration (FDA)-approved platinumbased drugs were understood to function primarily as DNA-damaging agents that form intra-and inter-strand cross-links. Intrastrand cross-links are removed largely by excision repair, whereas interstrand cross-links require homologous recombination (HR) and interstrand cross-link (ICL) repair. The latter generate single-or double-stranded breaks in the process 16 . However, despite the fact that oxaliplatin forms 1,2-intra-strand and other cross-links on DNA, like cisplatin and carboplatin, we found that oxaliplatin was most similar to compounds that inhibit transcription or translation (transcription-translation inhibitors) (Fig. 1c,d , Supplementary Table 2 and Supplementary Fig. 2a) . These results may begin to explain why oxaliplatin has a different cytotoxicity profile and clinical application than cisplatin or carboplatin. Additionally, RNAi signatures of cisplatin and oxaliplatin, when taken in combination with 5-fluorouracil (5-FU)-the primary drug with which oxaliplatin is paired-preserved these mechanistic differences (Supplementary Fig. 3 ). Prior analysis of NCI-60 data similarly concluded that oxaliplatin acts in a manner distinct from that of cisplatin and carboplatin, although no cellular function was identified as being responsible for the difference 17 . Notably, in this prior study, compounds clustered strictly by structure, which is indicative of the NCI-60 methodology's emphasis on drug metabolism and transport over mechanism of action 18 .
Interestingly, phenanthriplatin, a monofunctional and highly potent platinum(II) compound, also classified as a transcription-translation inhibitor (Fig. 1c,d, Supplementary Table 2 and Supplementary Fig. 2c ). Because phenanthriplatin is incapable of making DNA cross-links, yet also classifies as a transcription and translation inhibitor, like oxaliplatin, the ability of oxaliplatin to form cross-links on the DNA might be irrelevant to its mechanism of action. We went on to characterize seven additional platinum compounds and discovered that most also classified as DNA cross-linkers or transcription-translation inhibitors ( Supplementary Fig. 2b ,c and Supplementary Table 2) . Curiously, two monofunctional platinum agents, acriplatin and pyriplatin, were found to have mechanisms of action not represented in our reference set ( Supplementary Fig. 2d and Supplementary Table 2 ). This result suggests that potential mechanisms of action for platinum compounds extend beyond the scope of anti-cancer agents in current clinical use. Furthermore, these signature predictions are maintained in all permutations of leave-one-out cross-validation of the drugs in the reference set (Supplementary Table 3 ). Additionally, we used an indicator of structural similarity, the Tanimoto coefficient 19 , to cluster the compounds. Hierarchically, we found that structural clustering was unable to recapitulate RNAi-signature-based clustering, regardless of whether the compounds were clustered by their native structure or their anticipated structure once inside the cell (Supplementary Fig. 4) . Thus, mechanism cannot be correctly predicted on the basis of structure alone.
To more thoroughly examine the differences in RNAi signatures used to classify these molecules, we performed a detailed analysis of all of their signatures. The most notable differences included decreased resistance with shChk2 and decreased sensitivity with shChk1 for the transcription-translation-inhibitor-like compounds relative to the DNA-cross-linker-like compounds ( Fig. 1e and Supplementary Table 4 ). As another means of visualizing the data, we used principal-component analysis (PCA) to represent the variance of our data in fewer dimensions. After plotting all of our tested platinum analogs with canonical transcription-translation inhibitors, DNA-crosslinking agents and topoisomerase II (Top2) poisons, we saw that the transcription-translation inhibitors separated from DNA cross-linkers along the first principal component (PC1) (Fig. 1e) . Upon examining the variable contributions that made up PC1, we saw that shChk2 contributed most strongly among the hairpins. We also identified shChk2 as the greatest contributor to the distinction between these two sets of drugs in a p185 + BCR-Abl Cdkn2a Arf−/− mouse model of acute lymphoblastic leukemia (ALL) 20 (Supplementary Fig. 2e,f) .
DNA-damage response affects response to cisplatin but not oxaliplatin To confirm the RNAi-signature data using a parallel approach, we examined drug response in the avian DT40 cell line 21 . Here 40 different DT40 cell lines, each with a different gene knockout related to DNAdamage repair and tolerance, were dosed with five different platinum agents. In agreement with our RNAi signatures, the DT40 knockouts showed distinct sensitivities to oxaliplatin and phenanthriplatin relative to the other three platinum agents (Fig. 2a,b , and Supplementary  Tables 5 and 6 ). In particular, loss of genes involved in HR (XRCC2, XRCC3 and BRCA2) and ICR (FANCC, FANCD2 and FANCG) showed the greatest differences between the two categories of platinum agents. The relative lack of sensitivity of HR-and ICR-deficient cells to oxaliplatin suggests that it, as with phenanthriplatin, fails to form intra-and inter-strand cross-links. Interestingly, genes necessary for replication bypass (POLZ and PCNA) were critical for all of the platinum derivatives. This result suggests that oxaliplatin and phenanthriplatin treatment create lesions on the DNA that are toxic only in the absence of normal replication-bypass machinery. In addition, these results were recapitulated using RNAi against several genes related to DNA-damage repair and/or tolerance in Eµ-Myc Cdkn2a Arf−/− lymphoma cells and in Eµ-Myc Trp53 −/− lymphoma cells (Supplementary Fig. 5a,b) . Thus, relative drug sensitivities in the context of DT40 knockout cells support the RNAi-based category classifications.
Dependence on checkpoint kinases stratifies platinum agents Given the importance of the two cell-cycle checkpoint kinases, Chk1 and Chk2, in discriminating between the two mechanistic classes of platinum drug action and DNA-damage response signaling, we decided to first confirm that these distinctions are relevant in vivo. To do this, we conducted a cell-competition experiment using the Eµ-Myc Cdkn2a Arf−/− lymphoma cells that were partially infected with GFP-tagged shChk2 and then tail-vein injected into syngeneic recipient mice. Tumors from untreated, cisplatin-, oxaliplatin-or phenanthriplatin-treated mice were then analyzed for GFP percentage. As the in vitro data predicted, shChk2-containing cells were significantly enriched as compared to uninfected cells in mice treated with cisplatin, but not in mice treated with oxaliplatin or phenanthriplatin (Fig. 3a) . These results suggest that dependence on Chk2 activity, a key mediator of the canonical DNAdamage response, represents a primary distinction between the mechanistic classifications of DNA cross-linkers and transcriptiontranslation inhibitors.
Subsequently, we examined the cell-cycle profiles of cells treated with phenanthriplatin, oxaliplatin and cisplatin for 12 h at LD 80-90 . Oxaliplatin and phenanthriplatin induced a G1 cell-cycle arrest, whereas cisplatin arrested cells in the S and G2/M phases (Fig. 3b) .
We obtained similar results with the three drugs after 24 h of treatment in human lung adenocarcinoma and colorectal cell lines, A549 and LoVo, respectively (Supplementary Fig. 6 ). To determine the mechanistic basis for these cell-cycle differences, we examined signaling pathways that may be engaged following the induction of the DNA-damage response. As shown by western blot, p21 (encoded by CDKN1A) protein is activated more quickly in response to oxaliplatin and phenanthriplatin than to cisplatin (Supplementary Fig. 7a ). Additionally, knockdown of p21 sensitizes cells to oxaliplatin and phenanthriplatin treatment but elicits resistance to cisplatin (Supplementary Fig. 7b ).
Next, to gain further insight into DNA-damage signaling in response to these compounds, we examined the p53-activating kinase, Chk2. Chk2 is activated in response to double-strand breaks, whereby it goes on to phosphorylate p53 on serine 20 (serine 18 in mice), which relieves MDM2 (MDM2) inhibition of p53 (ref. 22 Relative GFP% is measured at 72 h by flow cytometry, and the subsequent shRNA signature is compared to our reference set using our modified K-nearest neighbors algorithm. (b) A schematic representation of our modified K-nearest neighbors algorithm. First, the test compound's nearest reference-set category is identified by Euclidian K-nearest neighbor's analysis. Second, the linkage ratio (LR) is determined by dividing the pairwise distances of the category containing the new drug by the category without the new drug. Third, the linkage ratios are then calculated for all out-of-category drugs as if they were members of the category in question. This generates a background distribution of negative-control linkage ratios. Fourth, the linkage ratio of the new drug is compared to the linkage ratio distribution of the negative controls to obtain a P value. If P > 0.05, then the drug is classified as belonging to a 'new class' and having a mechanism of action not represented in the reference set. (c) On the right, cisplatin and carboplatin, two of the three clinically approved platinum agents classify as DNA crosslinkers. On the left, oxaliplatin, the third clinically approved platinum agent, and phenanthriplatin, a monofunctional platinum agent, both classify as transcription-translation inhibitors. phenanthriplatin. We observed that treatment with oxaliplatin and phenanthriplatin resulted in γ-H2AX signal, but that this effect was not dependent on Chk2, as it was for cisplatin ( Fig. 3c,e) . All three drugs also elicited total p53 induction and phosphorylation of p53; however, this behavior was dependent on Chk2 for cisplatin (Fig. 3d) . Additionally, the same was observed for both γ-H2AX and p53 at 4 h, when comparing cisplatin and phenanthriplatin with and without shChk2 ( Supplementary  Fig. 8a,b) . Moreover, we observed upregulation of the p53 transcriptional targets Puma and Noxa following phenanthriplatin treatment, concomitant with the increase in p53 levels seen by western blot (Fig. 3d,f) . Subsequently, we examined γ-H2AX and phospho-ser18 p53 at and before 4 h. Phenanthriplatin, and to a lesser degree, oxaliplatin, induced γ-H2AX, phospho-ser18 p53 and total p53 accumulation, sooner and to a greater degree than cisplatin ( Supplementary Fig. 8c,d ). Phenanthriplatin and oxaliplatin also caused more rapid cell death than cisplatin and doxorubicin ( Supplementary Fig. 9 ). We confirmed that cisplatin-induced phosphorylation of serine 20 of p53 was Chk2-dependent in the human LoVo colorectal cell line ( Supplementary Fig. 10a ). Furthermore, transcript levels of the pro-apoptotic gene NOXA were increased following treatment with all platinum agents tested in multiple human cell lines ( Supplementary Fig. 10c-e) . Taken together, the early activation of apoptosis, along with the early appearance, persistence and Chk2 independence of γ-H2AX and phospho-ser18 p53, suggest a mechanism of cell death induced by oxaliplatin and phenanthriplatin that does not rely on canonical DNA-strand-break signaling.
Oxaliplatin does not induce a DNA-damage response Considering the aforementioned rapid induction of γ-H2AX signal and early apoptosis following oxaliplatin and phenanthriplatin treatment, we examined γ-H2AX via immunofluorescence to distinguish DNA-damage-related foci from pan-nuclear γ-H2AX; the latter is indicative of apoptosis 23, 24 . We observed, as expected, that cisplatin-treated cells had γ-H2AX foci characteristic of a DNA-damage response. However, similar to untreated cells, oxaliplatin-and phenanthriplatin-treated cells did not have γ-H2AX foci ( Fig. 4a-d) . Quantification of γ-H2AX signal showed that at both 4 h and 8 h, nearly all of the γ-H2AX signal in oxaliplatin-and phenanthriplatin-treated cells was derived from pan-nuclear γ-H2AX (Fig. 4c) . Additionally, in the human LoVo cell line, we confirmed that oxaliplatin-treated cells had substantially fewer γ-H2AX foci as compared to cisplatin-treated cells (Supplementary Fig. 10f ).
To further explain the absence of a DNA-damage response following treatment with oxaliplatin and phenanthriplatin, comet assays were performed 6 h after treatment. Comet assays test for the presence of smaller-weight DNA fragments produced following DNA breaks. A neutral comet assay, most sensitive to double-strand-DNA breaks, indicated that oxaliplatin and phenanthriplatin treatment results in significantly fewer double-strand breaks than untreated or cisplatin-treated mouse lymphoma or human breast cancer cells ( Fig. 4e and Supplementary Fig. 10g) . Interestingly, an alkaline comet assay, sensitive to both single-strand and double-strand breaks, indicated that only oxaliplatin treatment yielded significantly fewer DNA breaks than either no treatment or cisplatin treatment (Fig. 4f) . In the alkaline comet assay, S-phase cells yield longer tails than G1 or G2 cells. This result is consistent with having a large proportion of cells in S phase, as in the untreated condition, particularly relative to oxaliplatin and phenanthriplatin treatment 25 .
Oxaliplatin and phenanthriplatin induce ribosome biogenesis stress Our RNAi signatures predicted that the mechanism of action of oxaliplatin and phenanthriplatin would involve transcription or translation inhibition. To further explore this possibility, we first measured the amount of platinum on RNA and DNA after 3 h of cisplatin, oxaliplatin and phenanthriplatin treatment at LD 80-90 . Atomic-absorption spectroscopy revealed that all three compounds were present at appreciable amounts on both nucleic acids (Fig. 5a) . Interestingly, oxaliplatin treatment yielded the least amount of platinum on either nucleic acid-potentially because it has the lowest LD 80-90 concentration.
Defects in ribosome biogenesis can rapidly induce cell death in a p53-dependent and DNA-damage-independent manner 26 . Given the similarity between this type of cell death and that induced by oxaliplatin and phenanthriplatin treatment, we examined ribosomal RNA 
P h e n a n t h r ip (rRNA) synthesis following drug treatment. Indeed, we observed that within 30 min, pre-rRNA was decreased by nearly 50% in response to oxaliplatin and phenanthriplatin treatment (Fig. 5b) . At later time points, pre-rRNA was upregulated many-fold by oxaliplatin and phenanthriplatin exposure-a phenotype paralleled by actinomycin D, a known inducer of ribosome biogenesis stress 26 , but not by cisplatin (Fig. 5b) . Importantly, RNA polymerase II transcript levels were unaffected by treatment with any of the platinum agents ( Supplementary  Fig. 11) . Finally, to demonstrate on a functional genetic level that ribosome biogenesis stress was relevant to cell death caused by
Cisplatin-4 h Untreated P h e n a n t h r ip la t in U n t r e a t e d O x a li p la t in C is p la t in Foci/nucleus P h e n a n t h r ip la t in O x a li p la t in C is p la t in 4 h 8 h P h e n a n t h r ip la t in U n t r e a t e d O x a li p la t in C is p la t in P h e n a n t h r ip Oxaliplatin-4 h P h e n a n t h r ip 4 h 8 h P h e n a n t h r ip la t in U n t r e a t e d O x a li p la t in C is p la t in P h e n a n t h r ip Fig. 5c and Supplementary  Fig. 12a-c) . shRPL11 also induced resistance to oxaliplatin or phenanthriplatin treatment. Furthermore, we examined total p53 and cleaved poly-ADP ribose polymerase I (cPARP) levels with or without an RPL11 hairpin 12 h after treating with the platinum agents and actinomycin D (Fig. 5d and Supplementary Fig. 12d ). We saw that RPL11 knockdown led to diminished total p53 and cPARP levels in Independence, for the combination of rapamycin and oxaliplatin for which co-dosing was staggered, as shown. Data are represented as mean ± s.e.m. from three independent doses on independent cultures. (j) RNAi signatures for rapamycin oxaliplatin, the combination of the two doses simultaneously or oxaliplatin 6 h before rapamycin. Both combination signatures were more similar to rapamycin than oxaliplatin. a r t i c l e s 4 6 8 VOLUME 23 | NUMBER 4 | APRIL 2017 nature medicine cells treated with actinomycin D, oxaliplatin or phenanthriplatin, but not with cisplatin. This effect is particularly strong when accounting for p53 and cPARP induction caused by knockdown of an essential component of the ribosome such as RPL11. Thus, the ribosome-biogenesis-stress pathway is a central mediator of oxaliplatin and phenanthriplatin cytotoxicity. The localization of nucleolar proteins is altered in a characteristic manner in response to different types of cellular stress 27 , including
Transcript intensity (Z scores) SF_295  SF_539  SNB_19  SNB_75  U251  COLO205  HCC_2998  HCT_116  HCT_15  HT29  KM12  SW_620  CCRF_CEM  HL_60  K_562  MOLT_4  RPMI_8226  SR  LOXIMVI  MALME_3M  M14  SK_MEL_2  SK_MEL_28  SK_MEL_5  UACC_257  UACC_62  A549  EKVX  HOP_62  HOP_92  NCI_H226  NCI_H23  NCI_H322M  NCI_H460  NCI_H522  IGROV1  OVCAR_3  OVCAR_4  OVCAR_5  OVCAR_8  SK_OV_3  786_0  A498  ACHN  CAKI_1  RXF_393  SN12C  TK_10 Renal   SF_268  SF_295  SF_539  SNB_19  SNB_75  U251  COLO205  HCC_2998  HCT_116  HCT_15  HT29  KM12  SW_620  CCRF_CEM  HL_60  K_562  MOLT_4  RPMI_8226  SR  LOXIMVI  MALME_3M  M14  SK_MEL_2  SK_MEL_28  SK_MEL_5  UACC_257  UACC_62  A549  EKVX  HOP_62  HOP_92  NCI_H226  NCI_H23  NCI_H322M  NCI_H460  NCI_H522  IGROV1  OVCAR_3  OVCAR_4  OVCAR_5  OVCAR_8  SK_OV_3  786_0  A498  ACHN  CAKI_1  RXF_393  SN12C  TK_10 impaired translation. After 8 h of treatment of Eµ-Myc Cdkn2a Arf−/− lymphoma cells with the platinum agents and actinomycin D, we observed differences in the localization of nucleophosmin (NPM) and fibrillarin (FBL), two proteins normally localized to the nucleolus (Supplementary Fig. 13a ). Cisplatin treatment did not result in any cells with nucleolar (FBL) foci, whereas actinomycin D, oxaliplatin and phenanthriplatin treatment resulted in a modest increase relative to no treatment (Supplementary Fig. 13b ). More notably, NPM was found predominantly outside the nucleus for roughly 80% of cisplatin-treated cells, but not in the other conditions ( Supplementary  Fig. 13c ). The unique localization of nucleolar proteins among platinum agents further indicates that oxaliplatin and phenanthriplatin have a mechanism of action that is distinct from cisplatin and more similar to that of actinomycin D. Next, we sought to gain more insight into the influence that oxaliplatin may exert on translation machinery. To do so, we first examined the polysome profiles of Eµ-Myc Cdkn2a Arf−/− lymphoma cells after 6 h of treatment with cisplatin, oxaliplatin and phenanthriplatin. Cells treated with oxaliplatin or phenanthriplatin had significantly fewer polysomes relative to monosomes when compared to untreated or cisplatin-treated cells (Fig. 5e,f and Supplementary Fig. 14) . Thus, the global translation machinery is markedly perturbed by oxaliplatin treatment. Next, to demonstrate more directly the potential disruptive effect that oxaliplatin treatment had on translation, we quantified nascent protein synthesis by means of a click-chemistry compatible puromycin analog 28 . We observed in multiple cancer cell lines that oxaliplatin disrupts protein synthesis as early as 9 h after treatment ( Fig. 5g and Supplementary Fig. 15) .
If oxaliplatin impairs ribosomal function, we would expect to see an effect of oxaliplatin treatment on the efficacy of known translation inhibitors. To examine this possibility, we treated cells with a combination of rapamycin, an MTOR inhibitor and known ribosome-biogenesis-stress inducer, and either cisplatin or oxaliplatin. We then measured synergy or antagonism by comparing to the Bliss Independence additivity model 29 . We saw that the combination of cisplatin and rapamycin was additive, as indicated by the near-zero deviation from Bliss Independence (Fig. 5h) . However, the combination of oxaliplatin and rapamycin was highly antagonistic. Interestingly, this antagonism was not present if oxaliplatin was dosed before rapamycin, which indicates an epistatic relationship between the mechanisms of action of the two drugs (Fig. 5i) . To further study this relationship, we examined RNAi signatures to understand how the mechanisms of action varied in combination. Interestingly, the signature was more similar to rapamycin alone than oxaliplatin alone, whether dosed simultaneously or dosed with oxaliplatin 6 h before rapamycin (Fig. 5j) . This result suggests that active translation must be occurring for oxaliplatin to exert its cytotoxic effects.
Ribosome biogenesis stress sensitizes cells to oxaliplatin Next, we sought to determine whether ribosome biogenesis stress was a central determinant of oxaliplatin efficacy in human cells and across diverse tumor types. To perform this analysis, we used the NCI-60 human cancer cell line database, which includes gene-expression data for each cell line and its oxaliplatin treatment response. Using the CellMiner NCI-60 database query tool (https://discover.nci.nih. gov/cellminer/) 30 , we were able to probe for the genes for which expression in naive cells was correlated with sensitivity to oxaliplatin treatment. For example, RSL24D1, the gene most highly correlated to treatment sensitivity, is shown in comparison to the drugresponse profile of oxaliplatin ( Fig. 6a and Supplementary Fig. 16 ).
By performing gene-ontology annotation via DAVID on the list of 417 genes whereby expression was significantly correlated with oxaliplatin sensitivity, we identified an enrichment of terms related to translation, the ribosome and rRNA (Fig. 6b) 31, 32 . Additionally, gene-set enrichment analysis (GSEA) on the same set of genes identified "ribosome" as the only significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (Fig. 6c) 33 . Performing similar analysis for cisplatin at the same threshold used for oxaliplatin yielded only one gene, SFLN11. Whereas the previous analysis examined gene expression relative to the entire set of cell lines, we wanted to see whether the expression of translationmachinery was correlated with oxaliplatin sensitivity within particular cancer types. Indeed, we saw that in both lung and breast cancer cell lines, higher translation machinery expression was correlated with an increase in oxaliplatin sensitivity (Fig. 6d) .
We reasoned that this increased expression of translation machinery represents a 'translation addiction, ' and that ribosome-biogenesis-stress inducers kill by depriving the cell of translation machinery. Thus, a further increase of translation-machinery expression would buffer against translation-machinery-depriving treatments such as inducers of ribosome biogenesis stress. To examine this possibility, we knocked down PTEN (encoded by PTEN) to upregulate the MTOR pathway and thus elevate translation-machinery expression (Supplementary Fig. 17) . Indeed, upon knocking down PTEN, the cells were rendered more resistant to the known ribosome-biogenesis-stress inducers actinomycin D and 5-FU, as well as to oxaliplatin (Fig. 6e) . Interestingly, we also saw that PTEN knockdown sensitized cells to cisplatin.
We next wanted to explore how results these might be relevant to the clinic. Given the frequent use of oxaliplatin for the treatment of colorectal cancer, we examined whether translation addiction could underlie oxaliplatin efficacy in this disease, as opposed to cancers for which oxaliplatin shows little efficacy. We compared gene expression between all available colorectal and ovarian tumor samples from the The Cancer Genome Atlas (TCGA) 34, 35 . We then performed GSEA on all differentially expressed genes between the two cancer types. On the basis of genes that are upregulated in colorectal cancer relative to ovarian cancer, GSEA identified the 'ribosome' as one of the most enriched pathways that distinguishes colorectal cancer from ovarian cancer ( Fig. 6f and Supplementary Table 7) . GSEA did not identify any notable pathway enrichment from genes upregulated in ovarian cancer relative to colorectal cancer (Supplementary Table 8 ). Collectively, these data argue that the efficacy and clinical utility of oxaliplatin is derived from its ability to induce ribosome biogenesis stress.
Finally, we wanted to determine whether we could identify correlates of oxaliplatin response in cancers that are not typically thought to respond to oxaliplatin. Prior studies have indicated that APC (APC), a key negative regulator of the WNT pathway, loss in colorectal cancer causes a 'translation addiction' that is necessary for tumorigenesis 36 . Thus, we examined WNT-pathway genes and their correlation with translation-metagene expression in the TCGA expression databases 37 . Interestingly, we found that APC expression was significantly correlated with translation-metagene expression in several cancers, including breast and lung ( Fig. 6g and Supplementary Fig. 18 ). We chose breast cancer for further examination because the NCI-60 breast cancer cell lines had the strongest correlation between translationmachinery expression and oxaliplatin sensitivity. Using a panel of breast cancer cell lines, we confirmed that APC expression was correlated with oxaliplatin sensitivity (Fig. 6h) . Therefore, APC expression may represent a marker of oxaliplatin sensitivity in breast cancers, and potentially other cancers as well.
DISCUSSION
Our findings have important implications for the evaluation of small molecules and their derivatives in the clinic. First, in addition to potential changes in drug pharmacodynamics and pharmacokinetics, alterations in the nature of the ligands in platinum complexes have profound implications for primary mechanisms of action. Thus, platinum drugs might not function interchangeably with their derivatives in cancer regimens. This phenomenon explains an observed lack of efficacy for oxaliplatin in the treatment of malignancies conventionally treated by cisplatin, as well as the unanticipated and poorly understood value of oxaliplatin as a treatment for colorectal cancer [38] [39] [40] [41] . Second, changes in small-molecule structure can alter the molecular determinants of chemotherapeutic response. For example, instead of cisplatin, oxaliplatin has been tested as a front-line treatment for breast and non-small-cell lung cancer (NSCLC) [42] [43] [44] [45] [46] [47] . Furthermore, recent sequencing data have shown that greater than 10% of breast and non-small-cell lung cancers harbor inactivating mutations in ATM and CHEK2 (refs. 48,49) . Our data suggest that these mutant tumors may have differential responses to cisplatin and oxaliplatin. Thus, tumor mutations might represent important determinants of susceptibility to related platinum drugs.
Additionally, our data suggest that a 'translation addiction' in colorectal cancer is responsible for the effectiveness of oxaliplatin. Notably, other studies have indirectly associated the translation machinery with the mechanism of oxaliplatin-mediated cell killing. In one study, three oxaliplatin-resistant sublines were generated, and microarrays were performed to compare the resistant and parental cell lines 50 . In each pair of cell lines, a substantial portion of the differentially expressed transcripts between the resistant and parental lines corresponded to genes composing the ribosome. Another study generated an oxaliplatin-sensitivity predictor on the basis of NCI-60 oxaliplatin dose responses and cell line gene-expression data 51 , which enabled prediction of the responses to oxaliplatin in both cell lines in vitro as well as with patient colorectal cancer xenografts. Additionally, others used microarray technology to identify gene-expression signatures that best predicted outcomes in clinical colorectal cancer cases [52] [53] [54] [55] [56] [57] . Despite these unbiased approaches, their signatures consisted of ribosome components. Although this implies a role of the translation machinery in colorectal cancer, none of the aforementioned studies made such a connection.
MTOR-dependent translation elongation plays a crucial part in colorectal cancer tumorigenesis 36 . For example, APC-deficient lesions increase protein synthesis, such that the progression of tumorigenesis is prevented by rapamycin. Thus, translation addiction accompanies colorectal cancer progression, making rapamycin an attractive therapeutic option. Additionally, our data indicate that APC and the translation machinery are linked in other cancer types. However, despite numerous attempts, rapamycin has not attained a solid foothold in cancer treatment, owing in part to cell-intrinsic resistance mechanisms, such as compensatory upregulation of PI3K signaling 58 , and the development of rapamycin-insensitive MTOR mutations 59 . In cancer types for which rapamycin has failed in clinical trials, oxaliplatin may be viewed as a preferable choice for the inhibition of translation. Moreover, given the role of tumor-intrinsic WNT signaling in suppressing anti-tumor T cell immune responses 60 , therapies, such as oxaliplatin, that are more effective in WNT-activated tumors present a potential alternative to immunotherapy.
Although previous studies have identified differences in cellular response between cisplatin and oxaliplatin, ours is the first to identify causal links between oxaliplatin, ribosome biogenesis stress and cell death. For instance, oxaliplatin creates fewer cross-links per base than cisplatin, yet retains its cytotoxicity 61 . We suggest that the ability of oxaliplatin to cross-link DNA might be of questionable relevance, for we do not see activation of the DNA-damage response. However, oxaliplatin-modified DNA could still lead to the inhibition of rRNA synthesis, which would ultimately be responsible for ribosome biogenesis stress. In addition, one can envision scenarios in which oxaliplatinmodified rRNA, mRNA and/or protein could all potentially contribute to ribosome biogenesis stress. A DNA-damage-response-independent mechanism of cell death is consistent with previous observations that cisplatin-or oxaliplatin-resistant cell lines often do not exhibit crossresistance 3 . Finally, an analysis of the effects of various chemotherapeutics at a range of concentrations on rRNA synthesis and processing found that, at high enough concentrations, many agents-including cisplatin and oxaliplatin-perturb this process 62 . However, this study did not ascribe a causal link between ribosome biogenesis perturbation and cell death. Thus, although many chemotherapeutics may inhibit ribosome biogenesis at high drug concentrations, this behavior is unlikely to be their primary mechanism of action. Our findings demonstrate that, at clinically relevant and lower concentrations, oxaliplatin causes ribosome biogenesis stress, whereas cisplatin does not. Thus, our work demonstrates that perturbation of ribosome biogenesis is functionally important for oxaliplatin, but not cisplatin, to mediate cell death.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
